Showing results (21-30 of 52) with videos related to
Sort By:
Pageof 6
Therapeutic Advances in Medical Oncology|January 9, 2025
Real-world effectiveness and safety of second- or third-line pegylated liposomal irinotecan plus 5-fluorouracil and folinic acid in pancreatic ductal adenocarcinoma in SpainRafael Álvarez-Gallego, Roberto Pazo-Cid, Borja López de San Vicente, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 8, 2018
Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2Teresa Macarulla, Roberto Pazo-Cid, Carmen Guillén-Ponce, et al.Genome Medicine|April 20, 2023
ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNAAriana Huebner, James R M Black, Francesca Sarno, et al.Advances in Therapy|November 18, 2025
Tislelizumab + Chemotherapy in Gastric Cancer: Long-Term RATIONALE-305 Randomized Trial Follow-upMarcia Cruz-Correa, Do-Youn Oh, Ken Kato, et al.Cancers|December 11, 2022
Cytokines and Lymphoid Populations as Potential Biomarkers in Locally and Borderline Pancreatic AdenocarcinomaIranzu González-Borja, Antonio Viúdez, Emilia Alors-Pérez, et al.Current Medical Research and Opinion|June 18, 2025
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: patient-reported outcomes in the RATIONALE-305 studyMarcia Cruz-Correa, Rui-Hua Xu, Markus Moehler, et al.JCO Precision Oncology|January 24, 2025
Prevalence of FGFR2b Protein Overexpression in Advanced Gastric Cancers During Prescreening for the Phase III FORTITUDE-101 TrialSun Young Rha, Yanqiao Zhang, Anneli Elme, et al.NEJM Evidence|February 6, 2024
Nab-Paclitaxel plus Gemcitabine and FOLFOX in Metastatic Pancreatic CancerAlfredo Carrato, Roberto Pazo-Cid, Teresa Macarulla, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 9, 2024
First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 StudySusanna Hegewisch-Becker, Guillermo Mendez, Joseph Chao, et al.Lancet (London, England)|April 17, 2023
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trialKohei Shitara, Florian Lordick, Yung-Jue Bang, et al.Pageof 6